Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
53.48M | 51.13M | 131.83M | 7.60M | 135.00K |
Gross Profit | ||||
53.48M | -80.07M | 127.65M | 4.26M | -1.65M |
EBIT | ||||
-93.52M | -116.22M | -19.80M | -108.66M | -54.30M |
EBITDA | ||||
-90.22M | -114.27M | -17.82M | -107.19M | -53.41M |
Net Income Common Stockholders | ||||
-84.69M | -93.80M | -29.05M | -106.91M | -53.42M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
152.79M | 223.63M | 343.94M | 341.87M | 333.71M |
Total Assets | ||||
176.51M | 253.90M | 364.07M | 368.71M | 357.09M |
Total Debt | ||||
1.93M | 3.41M | 5.43M | 7.31M | 4.00M |
Net Debt | ||||
-82.78M | -107.86M | -154.09M | -327.11M | -322.18M |
Total Liabilities | ||||
25.38M | 41.82M | 84.56M | 80.29M | 70.26M |
Stockholders Equity | ||||
151.13M | 212.08M | 279.52M | 288.42M | 286.83M |
Cash Flow | Free Cash Flow | |||
-76.44M | -129.10M | -280.00K | -87.49M | -8.32M |
Operating Cash Flow | ||||
-76.44M | -127.16M | 322.00K | -85.80M | -6.08M |
Investing Cash Flow | ||||
49.47M | 78.04M | -175.78M | -1.68M | -9.76M |
Financing Cash Flow | ||||
542.00K | 842.00K | 880.00K | 95.56M | 247.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $10.27B | 20.71 | 23.13% | ― | 18.49% | 176.71% | |
68 Neutral | $36.51B | 42.41 | 17.33% | ― | 78.01% | ― | |
52 Neutral | $5.67B | ― | -31.26% | ― | 104.04% | 87.80% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
46 Neutral | $44.64M | ― | -46.63% | ― | 4.58% | 10.59% | |
40 Underperform | $35.01M | ― | 41.08% | ― | -0.55% | 49.85% | |
26 Underperform | $12.66M | 9.52 | >-0.01% | ― | ― | ― |
In January 2025, Repare Therapeutics announced a significant reorganization, including a 75% workforce reduction, to prioritize its Phase 1 clinical programs. This reorganization, approved on February 23, 2025, is expected to incur one-time costs of approximately $7.3 million for severance and $1.4 million for retention, with anticipated annual savings of $21 million. The departure of Chief Medical Officer Dr. Maria Koehler, effective March 31, 2025, is part of this restructuring, with severance benefits outlined. Retention bonuses are also being provided to key executives.
Repare Therapeutics announced a strategic shift to prioritize the advancement of its Phase 1 clinical programs, RP-1664 and RP-3467, along with exploring partnerships for other assets like Lunre+Camo. This re-alignment, coupled with cost and headcount reductions, is projected to extend the company’s cash runway to mid-2027, potentially enhancing its market position and creating value. Repare aims to achieve significant milestones in 2025, with initial clinical readouts for its prioritized programs and plans contingent on securing strategic partners for further developments.